Nahdi Medical Company (TADAWUL:4164)

Ligand Pharmaceuticals Income Statement

Financials in millions SAR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	9,879	9,446	8,714	8,616	8,066	8,642
Revenue Growth (YoY)	8.47%	8.41%	1.13%	6.82%	-6.67%	10.45%
Cost of Revenue	6,319	6,005	5,278	5,141	4,821	5,448
Gross Profit	3,560	3,441	3,436	3,475	3,245	3,194
Selling, General & Admin	2,696	2,598	2,499	2,500	2,397	2,269
Other Operating Expenses	-33.15	-27.91	-23.7	-24.3	-58.06	-23.08
Operating Expenses	2,662	2,570	2,475	2,475	2,339	2,228
Operating Income	897.23	871.66	960.74	999.82	905.94	966.17
Interest Expense	-95.06	-73.72	-50.46	-50.47	-78.88	-57.5
Interest & Investment Income	51.15	50.8	56.82	12.13	2.96	5.45
Currency Exchange Gain (Loss)	8.34	8.34	7.91	1.8	-	-
Other Non Operating Income (Expenses)	-42.14	-25.67	-31.47	-11.15	7.61	1.8
EBT Excluding Unusual Items	819.52	831.41	943.53	952.13	837.63	915.92
Gain (Loss) on Sale of Assets	1.54	1.54	0.22	-17.37	0.15	1.13
Asset Writedown	1.6	1.6	0.5	3.16	19.49	-22.6
Pretax Income	822.66	834.54	944.25	937.93	857.27	894.45
Income Tax Expense	-10.95	13.82	51.63	50.11	44.74	45.33
Net Income	833.61	820.72	892.62	887.81	812.53	849.12
Net Income to Common	833.61	820.72	892.62	887.81	812.53	849.12
Net Income Growth	-3.52%	-8.05%	0.54%	9.26%	-4.31%	22.70%
Shares Outstanding (Basic)	130	130	130	130	130	130
Shares Outstanding (Diluted)	130	130	130	130	130	130
Shares Change (YoY)	-	-	-	-	-	2500.00%
EPS (Basic)	6.41	6.31	6.87	6.83	6.25	6.53
EPS (Diluted)	6.41	6.31	6.87	6.83	6.25	6.53
EPS Growth	-3.52%	-8.05%	0.54%	9.26%	-4.31%	-95.28%
Free Cash Flow	1,114	1,152	962.17	1,418	1,051	1,290
Free Cash Flow Per Share	8.57	8.86	7.40	10.90	8.09	9.92
Dividend Per Share	5.600	5.500	5.500	5.310	-	-
Dividend Growth	1.82%	-	3.58%	-	-	-
Gross Margin	36.03%	36.43%	39.43%	40.33%	40.23%	36.96%
Operating Margin	9.08%	9.23%	11.03%	11.60%	11.23%	11.18%
Profit Margin	8.44%	8.69%	10.24%	10.30%	10.07%	9.83%
Free Cash Flow Margin	11.28%	12.19%	11.04%	16.45%	13.04%	14.93%
EBITDA	1,172	1,130	1,181	1,192	1,070	1,110
EBITDA Margin	11.87%	11.96%	13.55%	13.84%	13.26%	12.84%
D&A For EBITDA	275.16	258.31	219.86	192.36	164.03	143.75
EBIT	897.23	871.66	960.74	999.82	905.94	966.17
EBIT Margin	9.08%	9.23%	11.03%	11.60%	11.23%	11.18%
Effective Tax Rate	-	1.66%	5.47%	5.34%	5.22%	5.07%
Advertising Expenses	-	59.61	66.36	67.81	54.92	75.69

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.